PENTHROX has been used extensively for over 30 years in Australia, supervised by trained and authorised staff.4
It was assessed in a large, retrospective study, which examined patients from the databases linked to the Western Australian Ambulance Service between the years 1990-2004.5
- The purpose of this study was to determine whether the event rates of heart disease, renal disease, hepatic disease, diabetes or cancer increased in patients who received Methoxyflurane, compared with those not receiving Methoxyflurane.5
- Among the 17,629 patients who received methoxyflurane (81.7%-14,410 patients received methoxyflurane on a single occasion), there was no increase in the risk of disease occurrence (heart disease, renal disease, hepatic disease, diabetes or cancer) or death with the use of methoxyflurane to that of a non-methoxyflurane-administered group.5
Please refer to the Summary of Product Characteristics for full safety information, contraindications and adverse events. PENTHROX educational materials are available from Galen on request or they can be accessed here.